Improving on estimates of the relative harm to health from using modern ENDS (vaping) compared to tobacco smoking

Nick Wilson, Jennifer A Summers, Driss Ait Ouakrim, Janet Hoek, Richard Edwards, Tony Blakely

1 University of Otago, Wellington, New Zealand
2 Population Interventions, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia

ABSTRACT

Introduction: Although the harm to health from electronic nicotine delivery systems (ENDS) use relative to smoked tobacco remains highly uncertain, society and governments still need to know the likely range of the relative harm to inform regulatory policies for ENDS and smoking.

Methods: We identified biomarkers with specificity of association with different disease groupings e.g., volatile organic compound (VOCs) for chronic obstructive pulmonary disease; and tobacco-specific N’-nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons (PAHs) for all cancers. We conducted a review of recent studies (post January 2017) that compared these biomarkers between people exclusively using ENDS and those exclusively smoking tobacco. The percentage differences in these biomarkers were assumed to reflect the likely percentage difference in disease harm between ENDS and smoking, and were applied to previously modelled estimates of smoking-related health loss (in health-adjusted life-years; HALYs).

Results: The respective relative biomarker levels (ENDS vs smoking) weighted by study size and adjusted for acrolein from other sources were: 28% for respiratory diseases (five results, three studies); 42% for cancers (five results, four studies); and 35% for cardiovascular (seven results, four studies). When integrated with the HALY impacts by disease, the overall harm to health from ENDS was estimated to be 33% that of smoking.

Conclusions: This analysis suggests that the use of modern ENDS devices (vaping) could be a third as harmful to health as smoking in a high-income country setting. But this is probably best considered a maximal level given the potential biases in our method (i.e., the biomarkers used being correlated with more unaccounted for toxicants in smoking compared to with using ENDS).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
INTRODUCTION

The extent to which public health agencies and governments should restrict or support access to electronic nicotine delivery systems (ENDS), either as a means of quitting nicotine use or for harm reduction if long-term nicotine use persists, is controversial internationally. Previous estimates such as around 5% of the relative harm to health of ENDS use vs tobacco smoking,¹ ² are not disease-specific and have been critiqued, partly because they rely mainly on comparisons of emission levels from ENDS devices and tobacco smoking.³ ⁴ Studies of the relative harm of aerosol vs smoke are very limited because the relationships between emissions and biological outcomes remain unclear, and because ENDS users and smokers have different inhalation patterns. Other recent provisional review work on ENDS by a UK Government group makes only vague comments about ENDS having a “substantially lower” risk of adverse health effects compared to smoked cigarettes.⁵ A recent review of six studies reported that former smokers who transitioned to e-cigarettes “showed ~ 40% lower odds of respiratory outcomes compared to current exclusive smokers”.⁶ However, the authors also noted that “switching from smoking to e-cigarette[s] does not appear to significantly lower odds of cardiovascular outcomes.” Overall, many limitations affect interpretation of these studies, as five were cross-sectional and only one was longitudinal.

Changes in ENDS technology also suggest the likely relative harm may change over time as device design and quality control of manufacturing processes of the e-liquid and nicotine salt solutions evolve. Dynamic product development and manufacturing suggest that estimates of relative harm should be based on data from recently conducted studies of ENDS.

Despite uncertainty in the health effects of ENDS use, societies and policy-makers still need to make policy on how they are regulated. Their decision-making often relies on modelling studies (e.g., as per these ones⁷-¹⁸), which require up to date and credible estimates of harm arising from ENDS use relative to tobacco smoking. The most recent of these modelling studies used a relative harm range from 5% to 20%,¹⁸ but did not provide a detailed justification for these values. Improved quantification of the relative harm should improve policy-making and assist smokers deciding whether it is better to switch to ENDS use or continue trying to quit all nicotine products.

In the absence of adequate long-term epidemiological data on the health effects of ENDS use, studies comparing levels of biomarkers associated with the occurrence of adverse health outcomes between exclusive smokers and ENDS users may provide more valid comparisons of relative health impacts than reviews using mainly emissions-based data. That is, biomarkers will more closely represent the actual exposure of organs and tissues than will emissions-based studies. Select biomarkers for smoking-related toxicants are associated with key adverse health outcomes in smokers (Table 1), even though there is “variation in exposure due to differences in smoke composition across brands and to inherent variability among smokers.”¹⁹ Therefore in this study we conducted a review of relevant and recent biomarker data with the aim of producing an updated estimate for relative harm of ENDS use compared to smoking.
METHODS

To summarise, our method used the following three steps:

1. We identified biomarkers with specificity of association with different disease groupings: volatile organic compound (VOCs) for chronic obstructive pulmonary disease (COPD); tobacco-specific \( N^\prime \)-nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons (PAHs) for all cancers; and carbon monoxide and the VOC acrolein for cardiovascular disease (CVD).

2. We conducted a review of recent studies (published and with data collected after January 2017) that compared these biomarkers (in blood, urine and exhaled breath) between people exclusively using ENDS and those exclusively smoking tobacco, determining the percentage difference in these biomarkers between ENDS users and smokers.

3. These percentage differences in biomarkers were assumed to reflect the percentage difference in disease harm, and were applied to previously modelled estimates of smoking-related health loss (in health-adjusted life-years; HALYs) to produce disease-group-specific and overall estimates of health loss for ENDS use versus tobacco smoking.

**Linking key biomarkers with categories of health loss:** For this process we relied on a recent key World Health Organization Report detailing recent biomarker research.\(^{20}\) The details are in Table 1.

<table>
<thead>
<tr>
<th>Health loss from smoking</th>
<th>Biomarkers</th>
<th>Sources, comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>Volatile organic compounds (VOCs) e.g., acrolein, crotonaldehyde</td>
<td>The WHO(^{20}) considers these agents to be hazardous with acrolein considered to be: &quot;an intense irritant, is toxic to lung cilia and has been proposed as a lung carcinogen&quot;. Similarly, &quot;crotonaldehyde is a potent irritant and a weak hepatocarcinogen and forms DNA adducts in the human lung.&quot;</td>
</tr>
<tr>
<td>All cancers</td>
<td>Tobacco-specific ( N^\prime )-nitrosamines (TSNAs) Polycyclic aromatic hydrocarbons (PAHs)</td>
<td>The WHO(^{20}) notes that two of these TSNAs, &quot;NNK and NNN, are probably responsible for cancers of the lung, pancreas, oral cavity and oesophagus in tobacco users&quot;. &quot;Both have been classified as human carcinogens by working groups at [International Agency for Research on Cancer] IARC.&quot; (See Table 3 regarding NNK and NNN). The WHO(^{20}) notes that: &quot;many PAHs are potent carcinogens or toxicants in laboratory animals (57), and many are present in cigarette smoke, including the prototypic PAH benzo[a]pyrene, classified as a human carcinogen&quot; by a working group convened by the IARC.</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>Carbon monoxide (CO) Acrolein</td>
<td>The WHO(^{20}) states that: &quot;CO is a well established cardiovascular toxicant, which competes with oxygen for binding to haemoglobin. In smokers, it is considered to reduce oxygen delivery, cause endothelial dysfunction and promote the progression of atherosclerosis and other cardiovascular diseases&quot; The WHO(^{20}) reports that: &quot;cardiovascular tissues appear to be particularly sensitive to the toxic effects of acrolein&quot;. A review on this association has also been published.(^{21})</td>
</tr>
</tbody>
</table>
**Literature searches to identify relevant biomarker studies of the differences in biomarkers between ENDS users and smokers**: Searches of the peer-reviewed literature were conducted using PubMed and Google Scholar on 1 September 2020 using the names of relevant toxicants and biomarkers as listed in a FDA Review document (see Supplementary Information for further details and a PRISMA flow diagram: Tables A1 to A3).

We considered studies published from 1 January 2017 to 1 September 2020. To be included, studies had to compare exclusive ENDS users to exclusive tobacco smokers for the relevant biomarker in either urine, blood or exhaled air. Studies based on data collected prior to 1 January 2017 were excluded as we aimed to focus on the most recent ENDS devices and to increase the probability that relatively modern quality control measures were being used by the manufacturers of devices and e-liquids. Additional information describing the methodology of the review are provided in the Supplementary Information.

**Health loss by disease categories**: We used the results of a tobacco epidemiology and control modelling study, which has been extensively used for modelling tobacco control interventions. This model allows for the examination of tobacco control interventions on health across the whole life course in the population. It identifies HALYs gained from tobacco control interventions for the following four groupings: COPD, cancers (a grouping of 12 tobacco-associated cancers), cardiovascular disease, and lower respiratory tract infection. The results for these different condition groupings are detailed in Table 2.

Table 2: Health impacts by disease group as a result of modelling a tobacco control intervention (tobacco tax increases) at a national level

<table>
<thead>
<tr>
<th>Health condition / condition group</th>
<th>Proportion of HALYs gained* from preventing uptake and promoting quitting of smoking (undiscounted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>48.9%</td>
</tr>
<tr>
<td>Cancers (12 types**)</td>
<td>28.3%</td>
</tr>
<tr>
<td>Cardiovascular disease (coronary heart disease and stroke)</td>
<td>22.4%</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>0.4%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
</tr>
</tbody>
</table>

* Specifically from a tobacco tax intervention in New Zealand (a 10% per annum increase in tobacco tax from 2011 to 2031 that impacts on both increasing quitting and reducing youth uptake), and values from Table S6 in the S2 Supplementary Text of Blakely et al. The HALYs are for the 2011 population over the remainder of their lifespans. Therefore, many of the health gains are decades into the future. American Cancer Society’s Cancer Prevention Study II (CPS II) relative risks are used in this particular analysis (with results being similar to relative risks calculated from New Zealand studies).

**Cancers in descending order of importance as per the BODE preferred model: Lung cancer (26.0%), bladder cancer (1.3%), mouth and oropharyngeal cancer (0.9%), oesophageal cancer (0.9%), liver cancer (0.9%), pancreatic cancer (0.6%), stomach cancer (0.6%), kidney cancer (0.2%), cervical cancer (0.2%), thyroid cancer (0.0%), endometrial cancer (-0.2%), melanoma (-0.8%).

**Integration of the relative biomarker results with the health impact results**: Our final analysis integrated the results of the relative biomarker levels (taking the weighted mean result with weighting based on study participant total numbers), and the relative HALY impacts from the epidemiological model (Table 2). But as one particular toxicant, acrolein, has other sources (e.g., air pollution) we further adjusted the relative harm values for acrolein using data from the largest relevant study from the literature (Alwis et al., see Supplementary Information, Table A5). For this adjustment we assumed that other sources of acrolein (diet, air pollution etc) were non-differential between ENDS users and smokers.
For smokers who become ENDS users, the washout period used by the study may be important. That is for the biomarker NNAL, the half-life in the human body is 10 to 18 days. Our analysis did include two cross-sectional studies and one experimental study with eight weeks of follow-up using NNAL. But given this half-life issue, we excluded results for NNAL from one short-term experimental study lasting five days, where there would have been inadequate time for NNAL levels to have fully equilibrated with the transition to exclusive use of ENDS. But for all other biomarkers considered, half-lives were under 10 hours and so this need for a long washout period was not relevant (see Table 3 footnotes).

RESULTS

Identified biomarker studies

The results of our literature search and study selection process are shown in a PRISMA flow diagram (see Supplementary Information). Out of the 584 identified studies, five met our inclusion criteria by having appropriate comparison groups and data on contemporary ENDS devices (since 1 January 2017): Oliveri et al 2020, Jay et al 2020, Nga et al 2020, Boykan et al 2019, and Hatsukami et al 2020. Two were experimental studies, one quasi-experimental and two were cross-sectional. In terms of study quality, two of the five studies were funded by commercial interests in ENDS use/tobacco. Nevertheless, a particular advantage of one of these was that it kept users in a controlled environment (albeit only five days), which may have reduced the risks of contamination via undeclared dual use of ENDS use and tobacco products, as well as exposure to secondhand smoke/ENDS aerosol from others. Other study design limitations of the included studies included involving narrow demographic groups (e.g., those aged 12 to 21 years; and allowing participants to select products themselves, as opposed to being randomised. In the two cross-sectional studies, the authors had to rely on self-reporting as to participants being “exclusive” smokers or “exclusive” ENDS users. Further details on all these studies, including the specific ENDS products used are presented in the Supplementary Information (Table A4).

Many of the identified biomarker studies excluded from the analysis had collected data before our cut-off period of prior to January 2017 (e.g., ). Furthermore, some more recent studies did not involve appropriate comparison groups i.e., did not compare exclusive ENDS users with exclusive tobacco smokers (e.g., ). We excluded one study because participants had occupational exposure to volatile chemicals (i.e., workers in a chemical factory). Another study on exhaled VOCs, was excluded because it was unclear whether the exhaled chemicals could be considered to be solely biomarkers or whether these also involved un-metabolised aerosol/smoke from recent inhalation of the products.

Biomarker results by disease categories

Table 3 shows the results of the relative levels of the selected biomarkers. The mean results weighted by study size and adjusted for acrolein from other sources were: 28% for respiratory diseases (five results, three studies); 42% for cancers (five results, four studies); and 35% for CVD (seven results, four studies).
Table 3: Results from the recent biomarker studies identified involving use of modern ENDS products (and data on exclusive ENDS use and exclusive smoking with data collection since 1 January 2017)

<table>
<thead>
<tr>
<th>Study</th>
<th>Level in exclusive ENDS users [A]</th>
<th>Level in exclusive smokers [B]</th>
<th>% of [A] relative to [B]</th>
<th>ENDS users (N)</th>
<th>Smokers (N)</th>
<th>Additional details* (with further details in the Supplementary Information)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-cancer chronic respiratory disease (VOCs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jay et al 2020[^32]</td>
<td>0.2</td>
<td>1.87</td>
<td>10.7%</td>
<td>60</td>
<td>15</td>
<td>3-HPMA; within group experiment**; mean level in mg over 24 h (urine).</td>
</tr>
<tr>
<td>Hatsukami et al 2020[^36]</td>
<td>0.34</td>
<td>1.00</td>
<td>34.0%</td>
<td>58</td>
<td>63</td>
<td>CEMA (biomarker for acrylonitrile) showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td>Hatsukami et al 2020[^36]</td>
<td>0.53</td>
<td>1.00</td>
<td>53.0%</td>
<td>59</td>
<td>63</td>
<td>3-HPMA showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td>Hatsukami et al 2020[^36]</td>
<td>0.53</td>
<td>1.00</td>
<td>53.0%</td>
<td>58</td>
<td>63</td>
<td>HMPMA showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td>Oliveri et al 2020[^33]</td>
<td>655.1</td>
<td>1232.4</td>
<td>53.2%</td>
<td>59</td>
<td>54</td>
<td>3-HPMA; cartridge based product. Least squares mean level in μg/g creatinine (urine).</td>
</tr>
<tr>
<td><strong>Weighted mean#</strong></td>
<td></td>
<td></td>
<td></td>
<td>40.5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All cancers (TSNAs and PAHs)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oliveri et al 2020[^33]</td>
<td>28.6</td>
<td>230.1</td>
<td>12.4%</td>
<td>59</td>
<td>57</td>
<td>Total NNAL; ng/g creatinine (urine), least squares mean level; cartridge based product</td>
</tr>
<tr>
<td>Boykan et al 2019[^35]</td>
<td>10</td>
<td>56</td>
<td>17.9%</td>
<td>51</td>
<td>9</td>
<td>Total NNAL (the proportion above threshold of 14.5 pg/mL, %); aged 12 to 21 years old; convenience sample of outpatients.</td>
</tr>
<tr>
<td>Jay et al 2020[^32]</td>
<td>6.1</td>
<td>15.8</td>
<td>38.6%</td>
<td>60</td>
<td>15</td>
<td>NNN; mean ng over 24 h (urine); within group experiment**; the authors noted some anomalous results for NNN that concerned them.</td>
</tr>
<tr>
<td>Hatsukami et al 2020[^36]</td>
<td>0.47</td>
<td>1.00</td>
<td>47.0%</td>
<td>56</td>
<td>76</td>
<td>Total NNAL showing ratio relative to exclusive smoking; RCT; within group relative change**. There was little difference between the relative levels at 4 weeks (0.44) and 8 weeks (0.47).</td>
</tr>
<tr>
<td>Hatsukami et al 2020[^36]</td>
<td>0.79</td>
<td>1.00</td>
<td>79.0%</td>
<td>56</td>
<td>62</td>
<td>PhET (phenanthrene tetraol) a PAH showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td><strong>Weighted mean#</strong></td>
<td></td>
<td></td>
<td></td>
<td>41.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular disease (CO and acrolein)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jay et al 2020[^32]</td>
<td>0.2</td>
<td>1.87</td>
<td>10.7%</td>
<td>60</td>
<td>15</td>
<td>3-HPMA; within group experiment**; mean level in mg over 24 h (urine).</td>
</tr>
<tr>
<td>Jay et al 2020[^32]</td>
<td>1.9</td>
<td>7.0</td>
<td>27.1%</td>
<td>60</td>
<td>15</td>
<td>COHb in blood (percent saturation); within group experiment**</td>
</tr>
</tbody>
</table>
### Study Level in exclusive ENDS users [A] Level in exclusive smokers [B] % of [A] relative to [B] ENDS users (N) Smokers (N) Additional details* (with further details in the Supplementary Information)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nga et al 2020</td>
<td>6.40</td>
<td>16.47</td>
<td>38.9%</td>
<td>15</td>
<td>15</td>
<td>eCO as end tidal CO at 45 minutes; quasi-experimental with no randomisation (participants allowed to select products)</td>
</tr>
<tr>
<td>Hatsukami et al 2020</td>
<td>0.43</td>
<td>1.00</td>
<td>43.0%</td>
<td>58</td>
<td>76</td>
<td>eCO showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td>Hatsukami et al 2020</td>
<td>0.53</td>
<td>1.00</td>
<td>53.0%</td>
<td>59</td>
<td>63</td>
<td>3-HPMA showing ratio relative to exclusive smoking; RCT; within group relative change**</td>
</tr>
<tr>
<td>Oliveri et al 2020</td>
<td>655.1</td>
<td>1232.4</td>
<td>53.2%</td>
<td>59</td>
<td>54</td>
<td>3-HPMA; cartridge based product. Least squares mean level in μg/g creatinine (urine).</td>
</tr>
<tr>
<td>Oliveri et al 2020</td>
<td>2.2</td>
<td>4.1</td>
<td>53.7%</td>
<td>61</td>
<td>62</td>
<td>COHb in blood, least squares mean level; cartridge based product</td>
</tr>
<tr>
<td><strong>Weighted mean#</strong></td>
<td></td>
<td></td>
<td><strong>42.9%</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Terms and acronyms:
- 3-HPMA: 3-Hydroxypropylmercapturic acid, a metabolite of acrolein. Half-life: 5-9 hours.55
- CEMA: 2-cyanoethylmercapturic acid (biomarker for acrylonitrile). Half-life: 8 hours.56
- CO: carbon monoxide
- COHb: Carboxyhaemoglobin, carbon monoxide measured from a blood sample, % saturation. Half-life: 5-9 hours.55
- eCO: Exhaled carbon monoxide
- HMPMA: 3-hydroxy-1-methylpropylmercapturic acid (biomarker for crotonaldehyde/methylvinyl ketone). Half-life: 5-9 hours.55
- NNN: N-nitrosornicotine. Half-life: 45 minutes.55
- PAH: Polycyclic aromatic hydrocarbons
- PheT (phenanthrene tetraol), a PAH. Half-life: 8 hours.57
- RCT: Randomised controlled trial
- Total NNAL: (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) and its glucuronides, NNAL-O-glucuronide, and NNAL-N-glucuronide (ng/g creatinine). Half-life: 2-6 hours.58
- TSNAs: Tobacco-specific N’-nitrosamines
- VOCs: Volatile organic compounds

** By “within group” we compared the results at the start of the study when participants were all smokers with the results for the same group of individuals when they had all become ENDS users. All other comparisons in this table were between separate groups of exclusive ENDS users and exclusive smokers.

# Mean for category, weighted by total number of study participants (ENDS users plus smokers).

### Integrated analysis of biomarkers and health loss

When integrated with the HALY impacts from a tobacco tax intervention, by disease grouping, and with downward adjustments due to acrolein from other sources, the overall harm to health from ENDS was estimated at 33.2% that of smoking (Table 4).
Table 4: Integrated analysis of the relative harm from using modern ENDS devices relative to smoking tobacco in terms of health loss in HALYs by disease grouping

<table>
<thead>
<tr>
<th>Disease grouping</th>
<th>% HALY loss (Table 2) [A]</th>
<th>Relative harm of ENDS use vs smoking (Table 3 plus adjusted for acrolein from other sources) [B]</th>
<th>Relative harm in terms of HALY loss (i.e., [A] x [B])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>48.9%</td>
<td>27.6%*</td>
<td>13.5%</td>
</tr>
<tr>
<td>Cancers (12 types)</td>
<td>28.3%</td>
<td>41.8%</td>
<td>11.8%</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>22.4%</td>
<td>34.7%*</td>
<td>7.8%</td>
</tr>
<tr>
<td>Lower respiratory tract infection</td>
<td>0.4%</td>
<td>27.6%* (as per COPD**)</td>
<td>0.1%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
<td>33.2%</td>
<td></td>
</tr>
</tbody>
</table>

* Adjusted for the best estimate of acrolein from non-smoking sources (e.g., diet) at 20.1% of the level in smokers\(^\text{a}\) (see Supplementary Information).

** The basis for using the COPD approach is that “acrolein has powerful immune-suppressive effects on innate and adaptive immune cells”.\(^\text{c}\) Furthermore, in the pathogen interaction studies in mice, exposure to acrolein after infection markedly worsened pulmonary immune defences.\(^\text{d}\)

**DISCUSSION**

This analysis combined recent biomarker data from ENDS use (relative to smoking) with modelled smoking health loss data to produce an overall estimate of relative harm for ENDS for four of the main disease groupings caused by smoking tobacco. We estimated that the harm associated with modern ENDS to be 33% of the harm associated with tobacco smoking. This value is higher than previously suggested (e.g., at around 5%\(^\text{1,2}\)) and the range of relative harm values (5% to 20%)\(^\text{18}\) used in the most recent modelling study we identified.

But this 33% estimate should probably be considered a maximal level given potential biases in our method. A key such potential bias is that there may be more unmeasured toxicants correlated with the biomarkers we measured in smokers compared to ENDS users. Our reasoning is as follows. There are over 7000 chemicals in tobacco smoke, hundreds of which are toxic and around 70 which cause cancer.\(^\text{60}\) In contrast, the best estimate we identified to date was of “over 80” chemicals in ENDS aerosol.\(^\text{61}\) Now assume the “representative” toxicant biomarker we used in our analysis for each disease did not capture all the causal mechanisms of tobacco smoking with disease (either directly or by correlation), and that the occurrence of other correlated toxicants and mechanisms from ENDS use is less than with smoking tobacco (as suggested by the numbers of chemicals above), our method will likely have overestimated the percentage of harm from ENDS use as compared to smoking. For example, let us assume that acrolein is causally responsible for 60% of excess COPD due to smoking but 80% of excess COPD due to ENDS use (while ignoring toxicants and mechanisms correlated to acrolein). Then our method assumes all of the COPD variation can be explained by acrolein (100%/60% = 1.67 times overestimated). If we then apply it to ENDS use, this would lead to a net 1.33-fold over-estimate (80% times 1.67). The net bias will vary further due to toxicants correlated to acrolein in ENDS aerosol. Indeed, in the unlikely circumstance of there being many other correlated toxicants with ENDS use (or a few very potent correlated toxicants), our method may actually under-estimate the harm from ENDS – but we believe this to be very unlikely.
To illustrate the potential relevance of toxicants we have not included in our analysis, there is a systematic review\textsuperscript{62} which reported that: “Most metal/metalloid levels found in biosamples of e-cigarette users were similar or higher than levels found in biosamples of conventional cigarette users, and even higher than those found in biosamples of cigar users.” We also did not identify any biomarker data relating to formaldehyde, which is commonly detected in ENDS products.\textsuperscript{63} Similarly, we did not include fine particulates from ENDS, which may play a role in CVD.\textsuperscript{64} Flavourings also differ between ENDS products, and may have unique lung damaging effects.\textsuperscript{65} We also did not include studies of biomarkers of tissue/physiological impact (e.g., respiratory lung inflammation, platelet aggregation etc) given the lack of validation relative to chronic disease outcomes and/or because of the lack of direct comparisons between smoking and ENDS use.

Other limitations of our work include the following:

- Another reason why we may have over-estimated the relative harm of ENDS is that some exclusive ENDS users may have been ex-smokers, some of whom may have still been smoking. This would result in an underestimate of the true difference in exposure between the groups. This may have been less likely in the experimental studies as each included a measure expected to reduce the likelihood of this bias operating. These measures were use of incentives for compliance,\textsuperscript{36} confinement to maximise restriction to the allocated product type,\textsuperscript{32} and screening for evidence of continued smoking.\textsuperscript{34,35} Although there was variation in the findings between studies, the two cross-sectional studies,\textsuperscript{33,35} did not report a systematically higher level of biomarkers than the experimental studies, as might be expected if contamination by unreported continued smoking among exclusive ENDS users were greater in these studies.

- The disease categories we analysed covered the main groupings of tobacco-related disease, but omitted less major ones. For example, there is evidence that smoking causes diabetes and increases the risk of tuberculosis, various eye diseases and immune system disorders such as rheumatoid arthritis.\textsuperscript{19} Furthermore, some toxicants in ENDS products (e.g., acrolein) have also been associated with increasing the risk of diabetes.\textsuperscript{20}

- Within the disease categories we did not differentially weight particular toxicants by their likely importance in disease causation e.g., TSNAs vs PAHs in the “all cancers” grouping. While some work on relative prioritisation has been done (e.g., in tobacco-industry funded research\textsuperscript{66}), this work does not appear to be comprehensive enough to produce reliable rankings.

- The biomarker studies represent points in time in the long-term trajectory of ENDS use by individuals and within populations. Trajectories of ENDS use and smoking may diverge further in the future. For example, smoked tobacco products have changed little over many decades and we suspect that many smokers will continue smoking long term at approximately the same intensity. However, we are less certain for ENDS use. ENDS users may be more or less likely to continue ENDS use long term compared to smokers. There may also be future changes to ENDS technology and usage patterns that affect exposure levels among ENDS users (e.g., based on changes in relative nicotine levels, or potential delineation of smoke-free and vape-free areas, or if public tolerance of ENDS increases relative to smoking, or if ENDS products evolve further).

- Some studies had limitations and potential biases in their assessment of specific biomarkers among ENDS users. For example, while our analysis adjusted for other
sources of acrolein (e.g. dietary sources), we did not have the data to adjust other biomarkers by exposure to secondhand smoke (or secondhand exposure to aerosol from ENDS). Nevertheless, such exposures are likely to be relatively minor given evidence that NNAL levels in non-smokers are typically 1-5% those of smokers (due to exposure to second-hand smoke).  

- Two of the five studies used in our main analysis were industry-funded. Given evidence that this conflict of interest is strongly associated with results favourable to the tobacco industry, indicating no harm of ENDS, further caution is required.

Potential research implications

The high level of uncertainty of the relative harm of ENDS use compared to smoking highlights the need to develop a stronger evidence base. Agencies that fund research should therefore commission further studies that measure a wider range of biomarkers in exclusive ENDS users and exclusive smokers (in addition to long-term epidemiological studies that measure health outcomes). Additional biomarkers in the short-term biomarker studies should include: PAHs, aromatic amines, acyclic amines, fine particulates and heavy metals. There may also be a need for expert elicitation exercises involving toxicologists and epidemiologists to estimate the uncertainty ranges. In the interim, however, modelling work done to inform the regulation of ENDS and smoking, should probably use wide uncertainty intervals (e.g., from the previous estimate of around 5% up to the maximal estimate of 33% suggested in this analysis).

Acknowledgements and funding support

This work had funding support from the Cancer Society of New Zealand (Research Contract: Collaboration for Cancer Research Aotearoa New Zealand (CCR)). We thanks Sophie Braznell from the University of Bath, United Kingdom, for helpful comments on the manuscript.

Competing interests: Nil.

References

4. Burrowes K, Beckert L, Jones S. Human lungs are created to breathe clean air: the questionable quantification of vaping safety “95% less harmful”. N Z Med J 2020;133(1517).


effects and nicotine, acrolein and formaldehyde exposure. *Addiction* 2018;113:1874-82.


